1000370-76-2

Usage

Uses

Used in Pharmaceutical Synthesis:
(R)-3-(2-Nitro-phenylamino)-pyrrolidine-1-carboxylic acid tert-butyl ester is used as an intermediate in the synthesis of pharmaceutical compounds for its ability to facilitate the creation of complex drug molecules.
Used in Medicinal Chemistry Research:
In the field of medicinal chemistry, (R)-3-(2-Nitro-phenylaMino)-pyrrolidine-1-carboxylic acid tert-butyl ester is used as a building block for the development of new drugs, particularly those aimed at treating cardiovascular and metabolic diseases, due to its structural properties that can be manipulated to target specific biological pathways.
Used in Drug Discovery and Development:
The tert-butyl ester moiety in the compound enhances its stability and pharmacokinetic properties, making it a valuable tool in drug discovery and development, where such properties are crucial for the effectiveness and safety of new pharmaceuticals.
Used in Anti-inflammatory and Anticancer Research:
(R)-3-(2-Nitro-phenylamino)-pyrrolidine-1-carboxylic acid tert-butyl ester is also studied for its potential anti-inflammatory and anticancer properties, indicating its use in research aimed at understanding and treating these conditions.
Used in Organic Synthesis:
In the broader field of organic synthesis, (R)-3-(2-Nitro-phenylaMino)-pyrrolidine-1-carboxylic acid tert-butyl ester serves as a versatile building block, contributing to the creation of a wide range of organic molecules for various applications.

Upstream product

• 1493-27-2 ortho-nitrofluorobenzene 
• 147081-44-5 (3S)-3-amino-1-(tert-butoxycarbonyl)-pyrrolidine 
• 147081-49-0 (R)-3-aminopyrrolidine-1-carboxylic acid tert-butyl ester 

Relevant academic research and scientific papers

New 'chemical probes' to examine the role of the hFPRL1 (or ALXR) receptor in inflammation

We report the development of the novel N-substituted benzimidazole 11 as a potent and selective human formyl peptide receptor-like 1 (hFPRL1) agonist. This compound and its less active enantiomer 12 were identified as useful tools for studying receptor function in vitro.

(HETERO) ARYL IMIDAZOLONE COMPOUND

PROBLEM TO BE SOLVED: To provide a novel compound that has an inhibitory action on prolyl hydroxylases (PHDs), and is useful as a treatment agent for inflammatory bowel diseases such as ulcerative colitis. SOLUTION: The present disclosure provides a (hetero) aryl imidazolone compound represented by the formula (I) or a pharmacologically acceptable salt thereof (where m, u, p, q and r each denote a specific integer, E, G, Q and T each denote a specific group such as N or CH, W and Z each denote a specific ring, R1 and R3 each denote a specific group such as a halogen atom). SELECTED DRAWING: None COPYRIGHT: (C)2021,JPOandINPIT

1-CYANO-PYRROLIDINE DERIVATIVES AS INHIBITORS OF USP30.

The present invention relates to novel compounds and methods for the manufacture of inhibitors of deubiquitylatingenzymes (DUBs). In particular, the invention relates to the inhibition of ubiquitin C- terminal hydrolase 30 or Ubiquitin Specific Peptidase 30 (USP30). The invention further relates to the use of DUB inhibitors in the treatment of conditions involving mitochondrial dysfunction and cancer. Compounds of the invention include compounds having the formula (I) (I) or a pharmaceutically acceptable salt thereof, wherein R1, R 2, R 3, m, L and X are as defined herein.